Medivir, Interim Report, 1 January – 30 June 2008

• Consolidated net sales were SEK 14.7 (66.8) m in the period. In May, Medivir signed an agreement with Tibotec Pharmaceuticals Ltd. on hepatitis C, triggering a SEK 46.2 m (EUR 5.0 m) payment. This amount has been allocated over the assessed agreement term, with SEK 3.9 m recognized as revenue.

• The loss after tax amounted to SEK -77.3 (-98.0) m.

• Earnings per share were SEK -3.71 (-5.84).

• Cash flow from operating activities was SEK 1.2 (-86.2) m.

• Liquid assets as of 30 June were SEK 329.2 (313.1) m.



For more information, please contact:
Rein Piir, CFO and VP, Investor Relations: +46 (0)8 546 83123 or +46 (0)70 853 7292.